Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.

Collett, Marc SHincks, Jeffrey RBenschop, KimberleyDuizer, Erwinvan der Avoort, HarrieRhoden, EricLiu, HongmeiOberste, M StevenMcKinlay, Mark AHartford, Marianne2018-04-302018-04-302017-02-01Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model. 2017, 215 (3):335-343 J. Infect. Dis.1537-66132793260810.1093/infdis/jiw542http://hdl.handle.net/10029/621869Immunodeficient individuals who excrete vaccine-derived polioviruses threaten polio eradication. Antivirals address this threat.enArchived with thanks to The Journal of infectious diseasesAdultAntiviral AgentsCohort StudiesFemaleHumansMaleMiddle AgedPhenyl EthersPoliomyelitisPoliovirus Vaccine, OralSingle-Blind MethodTreatment OutcomeViral LoadVirus SheddingVirus UncoatingAntiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.ArticleJ Infect Dis 2017; 215(3):335-43